Trial Outcomes & Findings for A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes (NCT NCT03165786)

NCT ID: NCT03165786

Last Updated: 2025-02-03

Results Overview

A reliable and valid psychological scale. It is a 5-point Likert scale \[0-4\], that is summed for a single total continuous scale score. Scores may range from 0-72. Higher numbers indicate greater fear of hypoglycemia.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

12 weeks

Results posted on

2025-02-03

Participant Flow

Subjects will be recruited through Chicago metropolitan area university medical centers, local diabetes websites, and organizations using flyers, e-announcements, and recruitment letters.

Participant milestones

Participant milestones
Measure
FREE Group
Cognitive behavioral therapy intervention with real-time continuous glucose monitoring. FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Control Group
Real-time continuous glucose monitoring
Overall Study
STARTED
5
5
Overall Study
COMPLETED
5
5
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
FREE Group
n=5 Participants
Cognitive behavioral therapy intervention with real-time continuous glucose monitoring. FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Control Group
n=5 Participants
Real-time continuous glucose monitoring
Total
n=10 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
5 Participants
n=5 Participants
5 Participants
n=7 Participants
10 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
4 Participants
n=7 Participants
6 Participants
n=5 Participants
Sex: Female, Male
Male
3 Participants
n=5 Participants
1 Participants
n=7 Participants
4 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants
n=5 Participants
5 Participants
n=7 Participants
10 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
5 Participants
n=5 Participants
5 Participants
n=7 Participants
10 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
5 participants
n=5 Participants
5 participants
n=7 Participants
10 participants
n=5 Participants
Hypoglycemia Fear Survey II - Worry subscale
36.6 units on a scale
STANDARD_DEVIATION 18.4 • n=5 Participants
38.8 units on a scale
STANDARD_DEVIATION 6.0 • n=7 Participants
37.7 units on a scale
STANDARD_DEVIATION 12.9 • n=5 Participants
Diabetes Self-management Questionnaire
56.2 units on a scale
STANDARD_DEVIATION 13.2 • n=5 Participants
52.2 units on a scale
STANDARD_DEVIATION 11.5 • n=7 Participants
54.2 units on a scale
STANDARD_DEVIATION 11.9 • n=5 Participants
A1C
7.2 percentage
STANDARD_DEVIATION 1.29 • n=5 Participants
7.96 percentage
STANDARD_DEVIATION 1.3 • n=7 Participants
7.58 percentage
STANDARD_DEVIATION 1.28 • n=5 Participants
Glycemic variability
66.04 mg/dL
STANDARD_DEVIATION 16.7 • n=5 Participants
79.3 mg/dL
STANDARD_DEVIATION 12.9 • n=7 Participants
71.03 mg/dL
STANDARD_DEVIATION 15.9 • n=5 Participants

PRIMARY outcome

Timeframe: 12 weeks

A reliable and valid psychological scale. It is a 5-point Likert scale \[0-4\], that is summed for a single total continuous scale score. Scores may range from 0-72. Higher numbers indicate greater fear of hypoglycemia.

Outcome measures

Outcome measures
Measure
FREE Group
n=5 Participants
Cognitive behavioral therapy intervention with real-time continuous glucose monitoring. FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Control Group
n=5 Participants
Real-time continuous glucose monitoring
Hypoglycemia Fear Scale Score (HFS_2)
21.4 units on a scale
Standard Deviation 10.9
38.6 units on a scale
Standard Deviation 8.2

SECONDARY outcome

Timeframe: 12 weeks

A reliable and valid behavioral scale, provides total continuous scale score, ranging from 0-81, higher numbers indicate better self-management.

Outcome measures

Outcome measures
Measure
FREE Group
n=5 Participants
Cognitive behavioral therapy intervention with real-time continuous glucose monitoring. FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Control Group
n=5 Participants
Real-time continuous glucose monitoring
Diabetes Self-Management Questionnaire Scale Score (DSMQ)
58.7 units on a scale
Standard Deviation 12.6
50.6 units on a scale
Standard Deviation 12.1

SECONDARY outcome

Timeframe: 12 weeks

Hemoglobin A1c represents the average blood glucose over a 2-3 month period and is an index of glycemic control. The American Diabetes Association recommends a hemoglobin A1C below 7% for most people with diabetes. Higher percentages indicate higher average blood glucose levels.

Outcome measures

Outcome measures
Measure
FREE Group
n=5 Participants
Cognitive behavioral therapy intervention with real-time continuous glucose monitoring. FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Control Group
n=5 Participants
Real-time continuous glucose monitoring
Glycemic Control, the Average Blood Glucose Over a 2-3 Month Period of Time.
6.94 percentage
Standard Deviation 1.29
7.66 percentage
Standard Deviation 1.02

SECONDARY outcome

Timeframe: 8 weeks

Population: Same as above

Twenty-four hour fluctuations in glucose measured by a continuous glucose monitor that provides interstitial glucose readings every 5 minutes. This is a continuous measure. A higher standard deviation reflects greater glycemic variability.

Outcome measures

Outcome measures
Measure
FREE Group
n=5 Participants
Cognitive behavioral therapy intervention with real-time continuous glucose monitoring. FREE: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Control Group
n=5 Participants
Real-time continuous glucose monitoring
Glycemic Variability
73.0 mg/dL
Standard Deviation 13.8
73.3 mg/dL
Standard Deviation 11.8

Adverse Events

FREE Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pamela Martyn-Nemeth, Professor

University of Illinois Chicago

Phone: (312) 996-7903

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place